276 related articles for article (PubMed ID: 26038471)
41. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa.
Bishop KS; Blumberg L; Trollip AP; Smith AN; Roux L; York DF; Kiepiela P
Int J Tuberc Lung Dis; 2001 Oct; 5(10):952-7. PubMed ID: 11605890
[TBL] [Abstract][Full Text] [Related]
42. Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis.
Shi D; Zhou Q; Xu S; Zhu Y; Li H; Xu Y
Infect Drug Resist; 2022; 15():4985-4994. PubMed ID: 36065280
[TBL] [Abstract][Full Text] [Related]
43. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.
Kim HJ; Kwak HK; Lee J; Yun YJ; Lee JS; Lee MS; Min SY; Park SK; Kang HS; Maeng YH; Kim SY; Kim SY; Kook YH; Kim YR; Lee KH
Int J Tuberc Lung Dis; 2012 Jan; 16(1):98-103. PubMed ID: 22236853
[TBL] [Abstract][Full Text] [Related]
44. Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis.
Kuhlin J; Davies Forsman L; Mansjö M; Jonsson Nordvall M; Wijkander M; Wagrell C; Jonsson J; Groenheit R; Werngren J; Schön T; Bruchfeld J
Clin Infect Dis; 2021 Nov; 73(9):e3511-e3517. PubMed ID: 33011791
[TBL] [Abstract][Full Text] [Related]
45. Structural and Mechanistic Insights into
Saw WG; Leow CY; Harikishore A; Shin J; Cole MS; Aragaw WW; Ragunathan P; Hegde P; Aldrich CC; Dick T; Grüber G
ACS Infect Dis; 2022 Jul; 8(7):1324-1335. PubMed ID: 35731701
[No Abstract] [Full Text] [Related]
46. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.
Scorpio A; Zhang Y
Nat Med; 1996 Jun; 2(6):662-7. PubMed ID: 8640557
[TBL] [Abstract][Full Text] [Related]
47. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
48. Pyrazinamide drug resistance in RpsA mutant (∆438A) of Mycobacterium tuberculosis: Dynamics of essential motions and free-energy landscape analysis.
Singh A; Somvanshi P; Grover A
J Cell Biochem; 2019 May; 120(5):7386-7402. PubMed ID: 30390330
[TBL] [Abstract][Full Text] [Related]
49. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran.
Doustdar F; Khosravi AD; Farnia P
Microb Drug Resist; 2009 Dec; 15(4):251-6. PubMed ID: 19857130
[TBL] [Abstract][Full Text] [Related]
50. New mutations in pncA of in vitro selected pyrazinamide-resistant strains of Mycobacterium tuberculosis.
Bamaga M; Zhang H; Wright DJ
Microb Drug Resist; 2001; 7(3):223-8. PubMed ID: 11759083
[TBL] [Abstract][Full Text] [Related]
51. Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA.
Dillon NA; Peterson ND; Feaga HA; Keiler KC; Baughn AD
Sci Rep; 2017 Jul; 7(1):6135. PubMed ID: 28733601
[TBL] [Abstract][Full Text] [Related]
52. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.
Yüksel P; Tansel O
New Microbiol; 2009 Apr; 32(2):153-8. PubMed ID: 19579692
[TBL] [Abstract][Full Text] [Related]
53. Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
Rajendran V; Sethumadhavan R
J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724
[TBL] [Abstract][Full Text] [Related]
54. Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan.
Miyagi C; Yamane N; Yogesh B; Ano H; Takashima T
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):111-6. PubMed ID: 14972380
[TBL] [Abstract][Full Text] [Related]
55. New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens.
Anthony RM; den Hertog A; Mansjö M; Werngren J
Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S71-S72. PubMed ID: 28043624
[TBL] [Abstract][Full Text] [Related]
56. Detection of Mutations in
Shrestha D; Maharjan B; Thapa J; Akapelwa ML; Bwalya P; Chizimu JY; Nakajima C; Suzuki Y
Curr Issues Mol Biol; 2022 Sep; 44(9):4132-4141. PubMed ID: 36135195
[TBL] [Abstract][Full Text] [Related]
57.
Kim NY; Kim DY; Chu J; Jung SH
Infect Chemother; 2023 Jun; 55(2):247-256. PubMed ID: 37407242
[TBL] [Abstract][Full Text] [Related]
58. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
Stehr M; Elamin AA; Singh M
Expert Rev Anti Infect Ther; 2015 May; 13(5):593-603. PubMed ID: 25746054
[TBL] [Abstract][Full Text] [Related]
59. Exploring of pyrazinamidase recombinant activity from PZA-sensitive and resistant Mycobacterium tuberculosis expressed in Escherichia coli BL21 (DE3).
Purkan P; Hadi S; Retnowati W; Sumarsih S; Wahyuni DK; Piluharto B; Panjaitan TM; Ifada C; Nadila A; Nabilah BA
Braz J Biol; 2024; 84():e278911. PubMed ID: 38422295
[TBL] [Abstract][Full Text] [Related]
60. Molecular investigation against the resistant mechanism of PncA mutated pyrazinamide resistance and insight into the role of pH environment for pyrazinamide activation.
Srivastava G; Darokar MP; Sharma A
J Biomol Struct Dyn; 2020 Jul; 38(11):3411-3431. PubMed ID: 31448694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
